Semax and Selank inhibit enkephalin-degrading enzymes from human serum
Lab research · 2001
- What was studied
- Human-serum enzyme assays
- Main finding
- Both peptides and certain fragments inhibited peptide-degrading enzymes in laboratory assays.
Semax IC50 · 10 microM
Reported findings and study design
Human-serum enzyme assays comparing Semax, Selank and peptide-degradation inhibitors.
Population or model Human-serum enzyme assays
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Semax IC50 | 10 microM | |
| Selank IC50 | 20 microM | |
| Puromycin comparator IC50 | 10 mM | |
| Active fragments | Five-amino-acid fragments inhibited degradation; three/four/six-amino-acid fragments did not |
IC50 values measure enzyme inhibition in vitro, not clinical potency or dose equivalence.
Source for these results ↗ · Reviewed 2026-10-29
Study limitations and source details
Study limitations
- Human-derived serum does not make this a patient trial.
- Assay concentrations and enzyme effects do not establish a clinical mechanism or benefit.
Source details
Journal publication
Indexed citation and English abstract checked; full methods and risk of bias not appraised.
Sources checked
Citation
N V Kost, O Iu Sokolov, M V Gabaeva, I A Grivennikov, L A Andreeva, N F Miasoedov, A A Zozulia. Semax and Selank inhibit enkephalin-degrading enzymes from human serum Bioorg Khim. 27(3):180–183
Study source ↗ · DOI 10.1023/a:1011373002885 · Bibliography entry · Link to this summary
Related compounds
Semax
A synthetic heptapeptide, Met–Glu–His–Phe–Pro–Gly–Pro (MEHFPGP). It combines residues 4–7 of adrenocorticotropic hormone (ACTH) with Pro–Gly–Pro and has been studied in ischemic stroke.
Selank
A synthetic heptapeptide, Thr–Lys–Pro–Arg–Pro–Gly–Pro (TKPRPGP). It extends the immune peptide tuftsin with Pro–Gly–Pro and has been studied in anxiety and neurobiology.